Drug Approval | June 19, 2023
Lupin launches Thiamine Hydrochloride Injection USP in the US
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
The company will submit its comprehensive response on these observations to the US FDA
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Subscribe To Our Newsletter & Stay Updated
